Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:IMVT News 11 December 2025 - 14 December 2025

Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant, Inc. (NASDAQ: IMVT) stock is closing out the week in focus after the company completed a major equity raise designed to bolster funding for its autoimmune pipeline—while its controlling shareholder, Roivant Sciences, stepped in as the largest buyer. As of the most recent market close ahead of Sunday, December 14, 2025, IMVT shares were around $26.42, up about 6.6% on the day, following heightened volatility and elevated trading activity during the week. Below is what changed, why it matters for investors tracking Immunovant stock, and how Wall Street-style consensus forecasts currently frame upside vs. risk. What’s driving Immunovant stock
14 December 2025
·····
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. (NASDAQ: IMVT) were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch of its lead FcRn inhibitor, IMVT‑1402, in Graves’ disease.Immunovant, Inc.+1 By late afternoon, Immunovant stock was trading around $25.75, up roughly 9% on the day, with an intraday range between $22.03 and $25.87, giving the company a market value of about $4 billion.Stock Titan That upbeat finish came despite an initial sell‑off; one early report noted shares dropped around 7%
11 December 2025
·····

Stock Market Today

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Anglo American share price slips as BofA turns neutral after copper outlook cut

Anglo American share price slips as BofA turns neutral after copper outlook cut

7 February 2026
Anglo American shares closed down 0.75% at 3,435 pence Friday after BofA Global Research downgraded the miner to “neutral” and raised its price target to 3,600 pence. Anglo cut its 2026 copper production guidance and warned of continued weakness at De Beers. The company expects $200 million in charges tied to its Chile copper operations in the second half of 2025.
Go toTop